Placebo-Controlled Studies and The Need for Expanded Disclosure Rules

Journal of the American Medical Directors Association

Volumn 10, Issue 6, 2009, Pages 441-442

  Kline, Thomas F ^a   Duskin, Laura M ^b  

^a Geriatric Medicine and Rehabilitation   (United States)

^b Geriatric Psychiatry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; PLACEBO;

ABNORMAL BEHAVIOR; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL RESEARCH; CLINICAL TRIAL; CONFLICT OF INTEREST; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FUNDING; HUMAN; INTERPERSONAL COMMUNICATION; LETTER; PATIENT SAFETY; PLACEBO EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 67649092162     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2009.02.017     Document Type: Letter

References (2)

1. Rappaport S.A., Marcus R.N., Manos G., et al. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc 10 (2009) 21-27
2. Abilify (aripiprazole) Tokyo, 101-8535 Japan: Bristol Myers-Squibb/Otsuka Pharmaceutical Co, Ltd; 2008. Available at: http://www.abilify.com/default.aspx?TC=97111&utm_source=google&utm_medium=cpc&utm_campaign=decision&utm_term=abilifymedication&utm_content=dbrandedmedications_textad_default_text_tc97111#. Accessed May 26, 2009.